Can Ultrasound be Used as an Alternative Tool for Pancreatic Cystic Disease Compared With MRI?

IF 1.6 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2025-04-13 DOI:10.1111/ajco.14170

Lu-ying Gao, Jiang Ji, Yu Xia, Ya Hu, Liyuan Ma, Aonan Pan, Yuang An, Nengwen Luo, Yuxin Jiang

{"title":"Can Ultrasound be Used as an Alternative Tool for Pancreatic Cystic Disease Compared With MRI?","authors":"Lu-ying Gao, Jiang Ji, Yu Xia, Ya Hu, Liyuan Ma, Aonan Pan, Yuang An, Nengwen Luo, Yuxin Jiang","doi":"10.1111/ajco.14170","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Rationale and Objectives</h3>\n \n <p>To analyze the ultrasound features of pancreatic cystic lesions and to compare contrast-enhanced sonography (CEUS) with magnetic resonance imaging (MRI) to investigate the diagnostic value of CEUS for pancreatic cystic lesions.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Patients with pancreatic cystic lesions who underwent CEUS examination and enhanced MRI from February 2022 to January 2023 at Peking Union Medical College Hospital were prospectively included. The diagnostic value of CEUS in the diagnosis of pancreatic cystic lesions was analyzed using postoperative histopathology as the gold standard and compared with enhanced MRI.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 17 patients with pancreatic cystic lesions were included, the CEUS diagnostic accuracy was 76.47% (13/17), the enhanced MRI diagnostic accuracy was 64.71% (11/17), and the diagnostic results of CEUS were in moderate agreement with those of enhanced MRI (<i>κ</i> = 0.52). The CEUS features of all lesions were categorized into four types: Type I, unilocular cystic type, five cases; Type II, microcystic lesion type, four cases; Type III, macrocystic lesion type, two cases; and Type IV, lesion with an enhanced solid component, six cases. There were two cases of Type I and one case of Type II simple cysts. Pancreatic pseudocysts were Type I in one case. Of the pancreatic serous cystadenomas, three cases were Type II, two cases were Type III, and one case was Type IV. The case of pancreatic mucinous cystadenoma was Type I. For the intraductal papillary mucinous neoplasm, four cases were all Type IV. For solid pseudopapillary tumors of the pancreas, one case was classified as Type IV. One case of pancreatic neuroendocrine tumor was classified as Type I.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>CEUS, as an economical, radiation-free, and effective imaging modality, can be an optional test for pancreatic cystic diseases and helps in their diagnosis and follow-up.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"439-444"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14170","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale and Objectives

To analyze the ultrasound features of pancreatic cystic lesions and to compare contrast-enhanced sonography (CEUS) with magnetic resonance imaging (MRI) to investigate the diagnostic value of CEUS for pancreatic cystic lesions.

Materials and Methods

Patients with pancreatic cystic lesions who underwent CEUS examination and enhanced MRI from February 2022 to January 2023 at Peking Union Medical College Hospital were prospectively included. The diagnostic value of CEUS in the diagnosis of pancreatic cystic lesions was analyzed using postoperative histopathology as the gold standard and compared with enhanced MRI.

Results

In total, 17 patients with pancreatic cystic lesions were included, the CEUS diagnostic accuracy was 76.47% (13/17), the enhanced MRI diagnostic accuracy was 64.71% (11/17), and the diagnostic results of CEUS were in moderate agreement with those of enhanced MRI (κ = 0.52). The CEUS features of all lesions were categorized into four types: Type I, unilocular cystic type, five cases; Type II, microcystic lesion type, four cases; Type III, macrocystic lesion type, two cases; and Type IV, lesion with an enhanced solid component, six cases. There were two cases of Type I and one case of Type II simple cysts. Pancreatic pseudocysts were Type I in one case. Of the pancreatic serous cystadenomas, three cases were Type II, two cases were Type III, and one case was Type IV. The case of pancreatic mucinous cystadenoma was Type I. For the intraductal papillary mucinous neoplasm, four cases were all Type IV. For solid pseudopapillary tumors of the pancreas, one case was classified as Type IV. One case of pancreatic neuroendocrine tumor was classified as Type I.

Conclusion

CEUS, as an economical, radiation-free, and effective imaging modality, can be an optional test for pancreatic cystic diseases and helps in their diagnosis and follow-up.

查看原文本刊更多论文

与MRI相比，超声可以作为胰腺囊性疾病的替代工具吗？

理由与目的：分析胰腺囊性病变的超声特征，对比超声造影（CEUS）与磁共振成像（MRI），探讨超声造影（CEUS）对胰腺囊性病变的诊断价值。材料与方法：前瞻性纳入2022年2月至2023年1月在北京协和医院行超声造影和增强MRI检查的胰腺囊性病变患者。以术后组织病理学为金标准，对比增强MRI，分析超声造影对胰腺囊性病变的诊断价值。结果：共纳入17例胰腺囊性病变患者，超声造影诊断准确率为76.47%(13/17)，增强MRI诊断准确率为64.71%(11/17)，超声造影诊断结果与增强MRI诊断结果基本一致（κ = 0.52）。所有病变的超声造影特征可分为4种类型：1型，单眼囊性，5例；II型，微囊性病变型，4例；III型，大囊性病变型，2例；IV型病变伴实性成分增强6例。1型单纯性囊肿2例，2型单纯性囊肿1例。1例胰腺假性囊肿为I型。胰腺浆液性囊腺瘤3例为ⅱ型，2例为ⅲ型，1例为ⅳ型。胰腺粘液性囊腺瘤1例为ⅰ型。导管内乳头状黏液性肿瘤4例均为ⅳ型，胰腺实性假乳头状肿瘤1例为ⅳ型，胰腺神经内分泌肿瘤1例为ⅰ型。超声造影作为一种经济、无辐射、有效的成像方式，可作为胰腺囊性疾病的可选检查，有助于其诊断和随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.